DS
RGLS

DRW Securities’s Regulus Therapeutics RGLS Stock Holding History

DRW Securities’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,125
Closed -$89K – 89
2018
Q2 		$89K Hold
1,125
– – 0.01% 92
2018
Q1 		$97K Buy
1,125
+292
+35% +$39.1K 0.01% 147
2017
Q4 		$104K Buy
+833
New +$105K 0.01% 434

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DRW Securities's RGLS Position: Q3 2018 in Review

DRW Securities sold out of Regulus Therapeutics (RGLS) in Q3 2018, closing a stake of 1,125 shares — an estimated $89K sold.

DRW Securities first reported a position in RGLS in Q4 2017 and held it in 3 quarters. The position peaked at $104K in Q4 2017. 36 funds tracked by Wall St. Rank hold RGLS as of Q3 2018.

  • DRW Securities reported no remaining Regulus Therapeutics position as of Q3 2018 after selling out during the quarter.
  • DRW Securities sold 1,125 Regulus Therapeutics shares in Q3 2018, an estimated $89K.
  • DRW Securities first reported a position in Regulus Therapeutics in Q4 2017 and held it in 3 quarters.
  • DRW Securities's Regulus Therapeutics position peaked at $104K in Q4 2017.
  • 36 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2018.

Based on DRW Securities's 13F filing for Q3 2018, filed 14 Nov 2018.